ReviewInternational journal of nanomedicine2026
Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of people worldwide are dying from cancer, with metastasis being the main cause of cancer-related deaths, but most of the drugs used to treat these patients have systemic toxicity. Fortunately, with the development and application of nanodrug delivery systems, a large amount of research has been conducted on inorganic nanocarriers represented by metal nanocarriers, as well as organic nanocarriers represented by liposomal nanoparticles and polymeric micelles, as delivery systems for antitumor substances. These nanocarriers can not only increase the solubility and stability of hydrophobic drugs and prolong their circulation time in the blood, but also enable the loaded drugs to have tumor-targeting properties. These characteristics make nanodrug delivery systems synergistically enhance efficacy and reduce toxicity in cancer treatment. In this review, we will introduce the composition of nanoparticle drug delivery system carriers, their advantages in cancer treatment, and focus on the targeting capabilities of nanoparticle drug delivery systems, as well as briefly introduce clinically approved nanodrugs. This provides a theoretical basis and direction for the continuous improvement of drug-loaded nanosystems and the acceleration of clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.